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Prevalence of high serum uric acid is increased in  
ambulatory subjects with hyperglycemia and dyslipidemia
A prevalência de hiperuricemia está aumentada em pacientes ambulatoriais com hiperglicemia e dislipidemia
Tânia Torres Rosa1; Ewandro Luiz Rey Moura2; Manuela Costa de Oliveira3; 
Gláucia Boff4; Luiz Fernando Junqueira Jr.5; Joel Paulo Russomano Veiga6
Introduction: Serum uric acid has been considered a marker or an element of the clinical and 
laboratory alterations in the metabolic syndrome. Objective: to evaluate the association between 
levels of serum uric acid (UA) and the following laboratory profile: fasting glucose ≥ 100 mg/dl, 
triglycerides ≥ 150 mg/dl and high density lipoprotein cholesterol (HDL-C) < 50 mg/dl in women 
and < 40 mg/dl in men. Method: In a cross-sectional survey, blood samples of 4,328 randomized 
outpatients aged from 20 to 102 years were analyzed. Results: The mean (interquartile range) UA 
level was higher in men (6.7; 2.4-12.5 mg/dl) and women (5.4; 2.0-12.2 mg/dl) with the laboratorial 
profile than in those without it (5.9; 0.90-33.8 mg/dl for men and 4.4; 0.8-30.0 mg/dl for women) 
(p < 0.0001). A significant increase in the prevalence of laboratory profile was observed in men 
(OR = 2.2 mg/dl; 95% CI: 1.2-3.9 mg/dl) and women (OR = 2.2 mg/dl; 95% CI: 1.4-3.5 mg/dl) with 
hyperuricemia. Conclusion: These results show the association between serum levels of uric acid 








Introdução: O ácido úrico sérico tem sido considerado um marcador ou componente das alterações clínicas 
e laboratoriais da síndrome metabólica. Objetivo: Avaliar a associação entre o ácido úrico sérico (AU) e o 
perfil laboratorial composto de glicemia de jejum ≥ 100 mg/dl, triglicerídeos ≥ 150 mg/dl e colesterol da 
lipoproteína de alta densidade (HDL-C) < 50 mg/dl nas mulheres e < 40 mg/dl nos homens. Método: Em 
estudo de corte transversal, amostras de sangue de 4.328 pacientes ambulatoriais não selecionados com 
idade variando de 20 a 102 anos foram examinadas. Resultados: A mediana (variação interquartil) do AU 
foi mais elevada nos homens (6,7; 2,4-12,5 mg/dl) e mulheres (5,4;2-12,2 mg/dl) que apresentaram o perfil 
laboratorial do que nos que não o apresentaram (5,9; 0,9-33,8 mg/dl para os homens e 4,4; 0,8-30 mg/dl 
para as mulheres) (p < 0,0001). Observou-se aumento significativo na prevalência do perfil laboratorial nos 
homens (razão de chance [RC] = 2,2 mg/dl; intervalo de confiança [IC] 95%: 1,2-3,9 mg/dl) e mulheres  
(RC = 2,2 mg/dl; IC 95%: 1,4-3,5 mg/dl) com hiperuricemia. Conclusão: Esses resultados mostram a as-
sociação dos níveis séricos do acido úrico com o perfil laboratorial da síndrome metabólica nesse grupo não 
selecionado de indivíduos brasileiros atendidos ambulatorialmente, sendo este um achado semelhante ao 
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Introduction
The investigation of different factors or risk markers is an 
important clinical task to prevent several chronic diseases, 
particularly cardiovascular ones. Many of these risks are well 
defined while others need to be identified. One relevant risk 
condition to health is the metabolic syndrome (MS), which 
comprises a cluster of combined clinical and laboratory 
abnormalities, including increased waist circumference, 
overweight or obesity, dyslipidemia, systemic arterial 
hypertension, and glucose intolerance or type II diabetes, all 
of which reflect insulin resistance and constitute important 
atherogenic risk factors(4). Individuals with MS still have 
increased susceptibility to fatty liver, polycystic ovary, 
asthma, sleep disturbances, and an increased risk for renal 
and atherosclerotic cardiovascular disease(10, 11, 13, 18).
Although the components of MS may suggest its 
diagnostic when combined, not a single specific marker 
of the disease exists, and the presence of at least three of 
those alterations is the requirement for diagnostic of the 
syndrome(10, 11). Uric acid (UA) is not considered a criterion 
for the diagnosis of MS, but some studies have shown an 
association between high levels of UA and the syndrome 
in different populations(3, 7, 15, 17, 21). This is a very important 
fact because levels of UA can vary in different populations, 
they are easily measured in a routine fashion, and can help 
in the identification of the syndrome by investigating for 
established risk factors. Furthermore, different populations 
worldwide may have distinctive metabolic peculiarities.
In the present work, we aimed to transversally evaluate, 
in an unselected sample of ambulatory subjects, the 
association between UA and a laboratory profile comprising 
hyperglycemia, hypertriglyceridemia and low HDL-C, 
which constitute the established laboratory criteria for 
the diagnostic of MS according to the revised National 
Cholesterol Education Program Adult Treatment Panel III 
(NCEP/ATPIII)(4) revised in 2005(11).
Method
Study population
This was a retrospective cross-sectional survey based 
on a laboratory database of blood examinations from 
the Clinical Pathology Central Laboratory of the Brasília 
University Hospital, Brasília, DF, Brazil. The study was 
conducted between 2002 and 2004 and blood samples of 
4,331 ambulatory subjects assisted in this hospital, 20 years 
old or older, of whom 1,464 were men (33.8%) and 2,864 
were women (66.2%), participated in the survey. Subjects 
came to the hospital for blood collection and general 
laboratory examination as part of their routine evaluation 
for different clinical conditions. For each subject examined 
only one laboratory examination result was obtained, so 
that the number of examinations was equal to the number 
of subjects.
Laboratory data
Individual blood samples were collected in the morning 
after an overnight fasting period of at least 12 hours. Serum 
lipid profile including high-density lipoprotein fractions of 
cholesterol (HDL-C) and triglycerides (TG) was obtained, in 
addition to serum fasting glucose (FG) and UA.
Elevated serum glucose was defined as fasting glucose 
≥ 100 mg/dl, and high HDL-C when serum concentration 
was > 40 mg/dl in men and > 50 mg/dl in women. 
Hypertriglyceridemia was characterized as serum TG 
concentration ≥ 150 mg/dl.
In order to verify the prevalence of the altered laboratory 
profile in association with the level of UA, the latter was 
stratified into three levels, having as the cutoff the upper 
quartile (75th percentile) of the range of values for the 
whole group of subjects according to gender: ≤ 4.8, 4.9 
to 7.2 and > 7.2 mg/dl for men and ≤ 3.4, 3.5 to 5.5 and 
> 5.5 mg/dl for women. Hyperuricemia was defined as UA 
concentration > 6 mg/dl in men and > 5 mg/dl in women, 
based on reference values in our population using the 
specified laboratory method.
Levels of serum TG, glucose, and UA were determined 
by enzymatic techniques, and the level of HDL-C was 
measured using the monophasic colorimetric method 
without precipitation, with a biochemical autoanalyser 
(Mega® Bayer, Germany)(19).
Statistical analysis
The normality of distribution of laboratory data and 
UA concentration, discriminated by gender according to 
different age groups, was initially tested by the Kolmogorov-
Smirnov test. Considering that they showed a skewed 
non-normal distribution, the median (interquartile range) 
of continuous laboratory variables was compared between 
age-grouped men and women employing the Kruskal-Wallis 
test with post-doc Dunns Multiple Comparison Test. The 
median of serum UA in subjects with and without the altered 
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Considering the full age range, the median (interquartile 
range) concentration of UA was observed to be significantly 
higher in men (6.0; 0.9-33.8 mg/dl) as compared to 
women (4.4; 0.8-30 mg/dl). Also, UA levels increased with 
age in both men (p = 0.003) and women (p < 0.0001). 
Comparisons between groups of men and women for each 
age range showed p < 0.0001 for each one (Figure 2).
In subjects with the laboratory profile the median of 
UA was higher than in those without it for both genders in 
the different age ranges (p = 0.02 ≤ 0.0001) (Figure 3). 
Regarding the association between serum concentration 
of UA and the altered laboratory profile for the overall age 
range, a higher median concentration of UA was found in 
Figure 1 – Prevalence of laboratory profile of the metabolic syndrome in men and 
women according to age distribution
*p-value for the comparison between men and women in each age range 
(chi-square test).
Figure 2 – Median (interquartile range) of serum uric acid in men (left clear boxes) 
and women (right dark boxes) according to age distribution
*p-value for the comparison between groups of men with the three different age 
ranges, and **p-value for the comparison between groups of women with the three 
different age ranges (Kuskal-Wallis test). Each pair-wised comparison between 
the groups with the different age ranges, for both men and women, showed a 
p < 0.001; by the post-hoc Dunn’s multiple comparison test. Comparisons 
between the groups of men and women for each age range showed a 
p < 0.0001; (Mann-Whitney test).
Figure 3 – Serum uric acid in men (left block of comparisons) and women (right 
block of comparisons) with (dark boxes) and without (white boxes) the laboratory 
profile of metabolic syndrome, according to age distribution
*p-values for the comparisons between subjects with and without the laboratory 
profile of MS in each age range (Mann-Whitney test). The data are expressed as 
median(interquartile range).
laboratory profile was compared in both genders employing 
the Mann-Whitney test. Proportions of categorical variables 
were compared using the chi-squared test. The odds 
ratio (95% CI) was calculated for the association between 
altered laboratory profile and serum UA stratified into three 
concentration levels. A statistically significant association or 
difference between variables was considered when a two-
tailed p value was equal to or less than 5% (p ≤ 0.05), and 
a weak or trend statistical significance when P value was 
between 5% and 10% (0.05 ≤ p ≤ 0.1). Processing analysis 
and graphic design of the data employed the SigmaStat® 
3.11/SigmaPlot 9.01 for Windows (Systat Software, Inc., 
USA, 2004) and the Prism 4 for Windows® (GraphPad 
Software, Inc., USA, 2005) software packages.
Results
Prevalence of metabolic abnormalities analyzed by 
gender and age was marginally greater in women (9.04%, 
259/2864) than in men (7.17%, 122/1464) (p = 0.06). 
According to gender discriminated by age, prevalence 
of the altered laboratory profile in the age range of 20-
39 was statistically similar in men (4.45%, 15/337) and 
women (3.86%, 25/646) (p = 0.49); in the age range 
of 40-59 the alterations also occurred similarly in men 
(8.75%, 55/628) and women (9.78 %, 136/1,390) 
(p = 0.24). Differently, in the age range of 60 years and 
over, metabolic alterations were observed to be more 
prevalent in women (11.83%, 98/828) than in men 
(7.01%, 35/499) (p < 0.001). The altered laboratory 
profile increased directly with age in both genders, except 
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men with alterations (6.7; 2.4-12.5 mg/dl) compared with 
those without it (5.9; 0.90-33.8 mg/dl) (p < 0.0001). The 
same was observed in women with the alterations (5.4; 
2-12.2 mg/dl) in relation to those without it (4.4; 0.8- 
30 mg/dl) (p < 0.0001).
Men with serum UA concentration equal to or greater 
than 7.2 mg/dl (upper quartile) had a 2.21-fold increase 
in the prevalence of the altered laboratory profile (95% CI, 
1.24-3.94), compared with those who had concentrations 
equal to or less than 4.8 mg/dL (lower quartile). Among 
women, prevalence of the altered profile was 2.26-fold 
greater for those with serum UA concentration between 3.5 
and 5.5 mg/dl (95% CI, 1.45-3.53), and 5.26-fold greater 
when serum UA was above 5.5 mg/dl ( 95% CI, 3.36-8.22), 
as compared with those who had concentrations of UA 
equal to or less than 3.4 mg/dl (Table).
Discussion
As expected, prevalence of the altered laboratory profile, 
established as a component of the diagnosis of metabolic 
syndrome, increased as the population becomes older, 
especially in women. In the group of women, the subset of 
those who were 60 years old or older showed the highest 
prevalence of the metabolic alteration, as compared to men 
in the same age range. This finding may be justified by a 
reduced estrogenic protection in the advanced climacteric 
period, where cardiovascular risk is higher, which is in 
accordance with other studies(9, 22, 27). This period in a 
woman’s life is associated with higher levels of LDL-C and 
lower levels of HDL-C(16). Regardless of this particularity, it 
is a well- established fact that the defined altered laboratory 
profile is associated with a higher risk of cardiovascular 
disease, diabetes mellitus II, microalbuminuria, and renal 
disease in both genders in any age range(13, 18).
High levels of LDL cholesterol and triglycerides and low 
levels of HDL cholesterol increase the cardiovascular risk 
two fold in healthy adults(24, 28). The atherogenic risk factor 
TC/HDL-C ratio had a strong association with coronary heart 
disease(2). Concurrent hypertriglyceridemia and low HDL-C 
are typical of insulin-resistant subjects and they constitute 
significant risk factors for cardiovascular disease(1).
But the relevant finding in our study was that, in any 
age range, both men and women with the laboratory 
metabolic alteration also showed increased levels of 
serum UA. Although UA is not included in the criteria for 
the diagnosis of metabolic syndrome, other studies have 
also shown a strong association between high serum 
concentrations of UA and this syndrome or its clinical 
and/or laboratory components(3, 7, 15, 17, 21). Recently, Sui 
et al.(26), in a prospective study of 8,429 men and 1,260 
women (20-82 years old) showed that higher serum UA is 
a strong and independent predictor of incident metabolic 
syndrome in men and women.
A possible explanation for the association between 
increased UA and the metabolic alterations which represent 
a hyperinsulinemic state would be the stimulant role of 
insulin on the reabsorption of sodium and urate in the 
proximal renal tubule(20, 23). In fact, the degree of insulin 
tolerance is inversely related to the renal clearance of 
urate(5). On the other hand, one independent association 
of TG and UA was previously demonstrated, and increased 
TG levels may be associated with decreased UA renal 
excretion(8).
Therefore, hyperuricemia may signal the presence of 
metabolic syndrome and it may also be an additional risk 
factor for the development of the clinical complications 
associated with the syndrome. In consequence, it seems 
important to routinely investigate serum UA level when this 
syndrome is suspected or when conventional laboratory 
Table 1  Odds ratio (95% CI) for the association between the laboratory profile of metabolic syndrome and 
serum concentration of uric acid in unselected Brazilian ambulatory patients aged 20-102 years
Men (uric acid concentration, mg/dl) Women (uric acid concentration, mg/dl)
≤ 4.8 4.9-7.2  7.2 ≤ 3.4 3.5-5.5 > 5.5
N 373 704 387 731 1.419 714
OR 1 1.3 2.2* 1 2.2** 5.2**
CI – 0.8-2.4 1.2-3.9 – 1.4-3.5 3.3-8.2
N: number of subjects; OR: odds ratio; CI: confidence interval.
*p = 0.009; **p = 0.001 (chi-square test).
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alterations of the syndrome are encountered. On the 
other hand, when hyperuricemia is detected, the search 
for conventional markers of the syndrome should always 
be considered. 
Furthermore, evidence suggests a relationship between 
UA levels and hypertension(12). Hyperuricemia is also 
associated with endothelial dysfunction(29), which may 
contribute to increase cardiovascular risk in hypertensive 
subjects. Moreover, hyperuricemia may be an important risk 
factor for kidney disease and may lead to the development 
and faster progression of renal disease(6, 14, 25).
One limitation of this study was its retrospective 
design. This type of design and analysis, together with 
an ambulatory population evaluated for a multiplicity of 
clinical, conditions, inherently increases the likelihood that 
bias influenced our findings. To this respect, we attempted 
to minimize bias by analyzing all patients who met the 
study inclusion criteria. Another limitation was that several 
confounding variables, in a non-healthy population that 
attended to the hospital for several reasons, could not be 
adjusted because the respective data were not obtained. 
Also, there is a possibility that older patients or patients with 
metabolic syndrome and arterial hypertension might be 
using diuretics or other drugs that could eventually increase 
uric acid levels. However, our objective was to identify an 
association between UA concentration and the laboratory 
profile, regardless of other possible comorbidities, and it is 
very unlikely that only some subjects in use of drugs can 
affect the results.
 In conclusion, in a cross-sectional survey of a Brazilian 
unselected ambulatory population, serum concentration 
of UA was higher in men than in women and increased 
with age in both genders. In all age ranges and more 
frequently in women, hyperuricemia stratified in three 
levels was associated with a clustered laboratory alteration 
represented by hyperglycemia, hypertriglyceridemia and 
low HDL-C. In men the frequency of the altered laboratory 
profile was higher when UA concentration was greater than 
7.2 mg/dl. These findings suggest that high levels of UA 
are a comorbiditie and may be a marker or component of 
an altered metabolic profile represented by the metabolic 
syndrome. Hyperuricemia should be considered an additional 
risk factor for different clinical conditions, which demand 
treatment. To our knowledge, this is the first observation 
about the association between the clustered laboratory 
components of metabolic syndrome and hyperuricemia, 
in an unselected Brazilian population, reproducing similar 
findings verified in other populations worldwide.
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